Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment. 2016

Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
Breast Cancer Now Research Unit, Division of Cancer Studies, Guy's Hospital, King's College London School of Medicine, London SE1 9RT, UK.

Our knowledge and understanding of the tumor microenvironment (TME) have been recently expanded with the recognition of the important role of innate lymphoid cells (ILC). Three different groups of ILC have been described based on their ability to produce cytokines that mediate the interactions between innate and adaptive immune cells in a variety of immune responses in infection, allergy, and autoimmunity. However, recent evidence from experimental models and clinical studies has demonstrated that ILC contribute to the mechanisms that generate suppressive or tolerant environments that allow tumor regression or progression. Defining the complex network of interactions and crosstalk of ILC with other immune cells and understanding the specific contributions of each type of ILC leading to tumor development will allow the manipulation of their function and will be important to develop new interventions and therapeutic strategies.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D002450 Cell Communication Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP. Cell Interaction,Cell-to-Cell Interaction,Cell Communications,Cell Interactions,Cell to Cell Interaction,Cell-to-Cell Interactions,Communication, Cell,Communications, Cell,Interaction, Cell,Interaction, Cell-to-Cell,Interactions, Cell,Interactions, Cell-to-Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016131 Lymphocyte Subsets A classification of lymphocytes based on structurally or functionally different populations of cells. Lymphocyte Subpopulations,Lymphocyte Subpopulation,Lymphocyte Subset,Subpopulation, Lymphocyte,Subpopulations, Lymphocyte,Subset, Lymphocyte,Subsets, Lymphocyte

Related Publications

Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
January 2019, Frontiers in immunology,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
May 2023, Cancers,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
December 2019, Seminars in cancer biology,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
August 2023, CNS neuroscience & therapeutics,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
June 2021, Cancer cell,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
January 2023, Frontiers in medicine,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
August 2022, Journal of experimental & clinical cancer research : CR,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
February 2019, Seminars in immunology,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
June 2022, Archives of pharmacal research,
Fabian Flores-Borja, and Sheeba Irshad, and Peter Gordon, and Felix Wong, and Ibrahim Sheriff, and Andrew Tutt, and Tony Ng
January 2021, Frontiers in immunology,
Copied contents to your clipboard!